FDA Expands Stelara to Pediatric Ulcerative Colitis

Company: Janssen Biotech (Johnson & Johnson) · Drug: Stelara (Ustekinumab) · Indication: Pediatric Ulcerative Colitis, Age 2+ · Regulatory Action: FDA Label Expansion · Date: August 28, 2026 Summary FDA approved Janssen’s Stelara, ustekinumab, for moderately to severely active ulcerative colitis in children aged two…